Frontiers | Neoadjuvant Systemic Therapies in Bladder Cancer
ASCO GU 2021: Phase II Study of Gemcitabine and Split-Dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy (RC) in Patients with Muscle-Invasive Bladder Cancer (MIBC)
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial - The Lancet Oncology
Somer Treats With Switch Maintenance in Bladder Cancer
AUA 2019: Prospective Phase IIl Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade UTUC
Neoadjuvant Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab for Muscle-Invasive Bladder Cancer - The ASCO Post
Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence - ScienceDirect
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study - ScienceDirect
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/ cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma | BMC Urology | Full Text
Introduction Dr. Sonpavde: Thank
ASCO GU 2022: Biomarker Analysis and Updated Clinical Follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy
Name and designation of procedure author(s)
Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer | Future Oncology
Frontiers | Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
Redefining Cisplatin-Eligibility for Muscle-Invasive Bladder Cancer | PracticeUpdate
Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function | In Vivo
Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma | springermedizin.de
European Urology on Twitter: "New Words of Wisdom from @E_Laukhtina @DrShariat Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive
Comparison of cisplatin-induced nephrotoxicity between single-dose and split -dose administration to rats - ScienceDirect
Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function | In Vivo
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology
Comparison of cisplatin-induced nephrotoxicity between single-dose and split -dose administration to rats - ScienceDirect
JCM | Free Full-Text | Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review
The Diagnosis and Treatment of Patients with Bladder Carcinoma (12.03.2021)
